PharmaMar Has Announced That AEMPS Has Authorized the APLICOV-PC Clinical Trial With Aplidin(R) for the Treatment of Patients With COVID-19
PR83840
PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin(R) (Plitidepsin) for the Treatment of Patients With COVID-19
MADRID, April 28, 2020 /PRNewswire=KYODO JBN/ --
- The objective of the trial is to evaluate the efficacy and safety of
plitidepsin in patients with COVID-19 requiring hospital admission
- Plitidepsin recently obtained positive results from in vitro studies on the
human HCoV-229E coronavirus, carried out at the National Biotechnology Center
(Centro Nacional de Biotecnología) of the Spanish National Research Council
(CSIC)
PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial
with Aplidin(R) (plitidepsin), for the treatment of patients with COVID-19,
which has been authorized by the Spanish Medicines and Healthcare Products
Agency (AEMPS).
This is a multicenter, randomized, parallel, open-label study to evaluate the
safety profile and efficacy of three doses of plitidepsin in patients with
COVID-19 requiring hospital admission.
Three hospitals from Madrid (Spain) will participate in the study. Three
cohorts of patients with three different dose levels will be included in the
study to assess the efficacy and safety of plitidepsin at each dose level
administered in patients admitted to hospitals with COVID-19.
During this first stage, 27 patients will be recruited, to whom three doses
will be administered. The viral load of the patients will be measured before
and after the treatment, as well as a series of other parameters for clinical
evolution. If the results were positive at this early stage, the trial would
continue at the optimal dose after discussion with the regulator, with a larger
cohort of patients.
On March 13th, the Company announced the results of in vitro studies of
plitidepsin on the human HCoV-229E coronavirus, which has a very similar
multiplication and propagation mechanism to SARS-CoV-2, as they both use the
eEF1A protein for their reproduction. The studies were carried out at the
National Biotechnology Center of the Spanish National Research Council (CSIC)
(see press release
[http://pharmamar.com/wp-content/uploads/2020/03/PR_Results_Aplidin_coronavirus.
pdf]).
Plitidepsin acts by blocking the protein eEF1A, present in human cells, which
is used by SARS-CoV-2 to reproduce and infect other cells. By means of this
inhibition, the expectation is that reproduction of the virus inside the cell
is prevented, making this propagation to the rest of the cells unviable.
Legal warning
This press release does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on
oncology and committed to research and development which takes its inspiration
from the sea to discover molecules with antitumor activity. It is a company
that seeks innovative products to provide healthcare professionals with new
tools to treat cancer. Its commitment to patients and to research has made it
one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program.
It develops and commercializes Yondelis(R) in Europe and has other
clinical-stage programs under development for several types of solid cancers:
lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy,
France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly
owns other companies: GENOMICA, a molecular diagnostics company; Sylentis,
dedicated to researching therapeutic applications of gene silencing (RNAi). To
learn more about PharmaMar, please visit us at www.pharmamar.com.
Logo - https://mma.prnewswire.com/media/1160908/PharmaMar_Logo.jpg
Source: PharmaMar
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。